ID   TBK1_HUMAN              Reviewed;         729 AA.
AC   Q9UHD2; A8K4S4; Q8IYV3; Q9NUJ5;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   12-OCT-2022, entry version 199.
DE   RecName: Full=Serine/threonine-protein kinase TBK1 {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960, ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, ECO:0000269|PubMed:25636800};
DE   AltName: Full=NF-kappa-B-activating kinase {ECO:0000303|PubMed:10783893};
DE   AltName: Full=T2K;
DE   AltName: Full=TANK-binding kinase 1 {ECO:0000303|PubMed:10581243};
GN   Name=TBK1 {ECO:0000303|PubMed:10581243, ECO:0000312|HGNC:HGNC:11584};
GN   Synonyms=NAK {ECO:0000303|PubMed:10783893};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH TANK AND TRAF2, AND
RP   MUTAGENESIS OF LYS-38.
RC   TISSUE=Spleen;
RX   PubMed=10581243; DOI=10.1093/emboj/18.23.6694;
RA   Pomerantz J.L., Baltimore D.;
RT   "NF-kB activation by a signaling complex containing TRAF2, TANK, and TBK1,
RT   a novel IKK-related kinase.";
RL   EMBO J. 18:6694-6704(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION IN PHOSPHORYLATION OF NFKBIA AND
RP   IKBKB, TISSUE SPECIFICITY, AND CATALYTIC ACTIVITY.
RX   PubMed=10783893; DOI=10.1038/35008109;
RA   Tojima Y., Fujimoto A., Delhase M., Chen Y., Hatakeyama S., Nakayama K.,
RA   Kaneko Y., Nimura Y., Motoyama N., Ikeda K., Karin M., Nakanishi M.;
RT   "NAK is an IkappaB kinase-activating kinase.";
RL   Nature 404:778-782(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-388 AND GLN-570.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, MUTAGENESIS OF SER-172, AND PHOSPHORYLATION AT SER-172.
RX   PubMed=11839743; DOI=10.1074/jbc.m110474200;
RA   Kishore N., Huynh Q.K., Mathialagan S., Hall T., Rouw S., Creely D.,
RA   Lange G., Caroll J., Reitz B., Donnelly A., Boddupalli H., Combs R.G.,
RA   Kretzmer K., Tripp C.S.;
RT   "IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-
RT   2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2.";
RL   J. Biol. Chem. 277:13840-13847(2002).
RN   [7]
RP   INTERACTION WITH TIRAP AND TICAM1.
RX   PubMed=14530355; DOI=10.4049/jimmunol.171.8.4304;
RA   Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K.,
RA   Akira S.;
RT   "Toll/IL-1 receptor domain-containing adapter inducing IFN-beta (TRIF)
RT   associates with TNF receptor-associated factor 6 and TANK-binding kinase 1,
RT   and activates two distinct transcription factors, NF-kappa B and IFN-
RT   regulatory factor-3, in the Toll-like receptor signaling.";
RL   J. Immunol. 171:4304-4310(2003).
RN   [8]
RP   FUNCTION.
RX   PubMed=12692549; DOI=10.1038/ni921;
RA   Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E.,
RA   Golenbock D.T., Coyle A.J., Liao S.-M., Maniatis T.;
RT   "IKKepsilon and TBK1 are essential components of the IRF3 signaling
RT   pathway.";
RL   Nat. Immunol. 4:491-496(2003).
RN   [9]
RP   FUNCTION.
RX   PubMed=12702806; DOI=10.1126/science.1081315;
RA   Sharma S., tenOever B.R., Grandvaux N., Zhou G.-P., Lin R., Hiscott J.;
RT   "Triggering the interferon antiviral response through an IKK-related
RT   pathway.";
RL   Science 300:1148-1151(2003).
RN   [10]
RP   INTERACTION WITH AZI2.
RX   PubMed=14560022; DOI=10.1128/mcb.23.21.7780-7793.2003;
RA   Fujita F., Taniguchi Y., Kato T., Narita Y., Furuya A., Ogawa T.,
RA   Sakurai H., Joh T., Itoh M., Delhase M., Karin M., Nakanishi M.;
RT   "Identification of NAP1, a regulatory subunit of IkappaB kinase-related
RT   kinases that potentiates NF-kappaB signaling.";
RL   Mol. Cell. Biol. 23:7780-7793(2003).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF IRF3, AND CATALYTIC ACTIVITY.
RX   PubMed=14703513; DOI=10.1074/jbc.m310616200;
RA   Mori M., Yoneyama M., Ito T., Takahashi K., Inagaki F., Fujita T.;
RT   "Identification of Ser-386 of interferon regulatory factor 3 as critical
RT   target for inducible phosphorylation that determines activation.";
RL   J. Biol. Chem. 279:9698-9702(2004).
RN   [12]
RP   INTERACTION WITH TICAM1.
RX   PubMed=14739303; DOI=10.1074/jbc.m311629200;
RA   Han K.J., Su X., Xu L.-G., Bin L.H., Zhang J., Shu H.-B.;
RT   "Mechanisms of the TRIF-induced interferon-stimulated response element and
RT   NF-kappaB activation and apoptosis pathways.";
RL   J. Biol. Chem. 279:15652-15661(2004).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15485837; DOI=10.1074/jbc.m411037200;
RA   Kuai J., Wooters J., Hall J.P., Rao V.R., Nickbarg E., Li B.,
RA   Chatterjee-Kishore M., Qiu Y., Lin L.-L.;
RT   "NAK is recruited to the TNFR1 complex in a TNFalpha-dependent manner and
RT   mediates the production of RANTES: identification of endogenous TNFR-
RT   interacting proteins by a proteomic approach.";
RL   J. Biol. Chem. 279:53266-53271(2004).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF RELA, AND CATALYTIC ACTIVITY.
RX   PubMed=15489227; DOI=10.1074/jbc.m409825200;
RA   Buss H., Dorrie A., Schmitz M.L., Hoffmann E., Resch K., Kracht M.;
RT   "Constitutive and interleukin-1-inducible phosphorylation of p65
RT   NF-{kappa}B at serine 536 is mediated by multiple protein kinases including
RT   I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family
RT   member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and
RT   couples p65 to TATA-binding protein-associated factor II31-mediated
RT   interleukin-8 transcription.";
RL   J. Biol. Chem. 279:55633-55643(2004).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF IRF7, AND CATALYTIC ACTIVITY.
RX   PubMed=15367631; DOI=10.1128/jvi.78.19.10636-10649.2004;
RA   tenOever B.R., Sharma S., Zou W., Sun Q., Grandvaux N., Julkunen I.,
RA   Hemmi H., Yamamoto M., Akira S., Yeh W.C., Lin R., Hiscott J.;
RT   "Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus
RT   infection and the role of viral ribonucleoprotein in the development of
RT   interferon antiviral immunity.";
RL   J. Virol. 78:10636-10649(2004).
RN   [16]
RP   INTERACTION WITH SIKE1; IRF3; TICAM1 AND DDX58.
RX   PubMed=16281057; DOI=10.1038/sj.emboj.7600863;
RA   Huang J., Liu T., Xu L.-G., Chen D., Zhai Z., Shu H.-B.;
RT   "SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-
RT   triggered IRF-3 activation pathways.";
RL   EMBO J. 24:4018-4028(2005).
RN   [17]
RP   INTERACTION WITH HCV NS3 (MICROBIAL INFECTION).
RX   PubMed=15841462; DOI=10.1002/hep.20666;
RA   Otsuka M., Kato N., Moriyama M., Taniguchi H., Wang Y., Dharel N.,
RA   Kawabe T., Omata M.;
RT   "Interaction between the HCV NS3 protein and the host TBK1 protein leads to
RT   inhibition of cellular antiviral responses.";
RL   Hepatology 41:1004-1012(2005).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH BORNA DISEASE VIRUS P PROTEIN.
RX   PubMed=16155125; DOI=10.1073/pnas.0502883102;
RA   Unterstab G., Ludwig S., Anton A., Planz O., Dauber B., Krappmann D.,
RA   Heins G., Ehrhardt C., Wolff T.;
RT   "Viral targeting of the interferon-beta-inducing Traf family member-
RT   associated NF-kappa-B activator (TANK)-binding kinase-1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13640-13645(2005).
RN   [19]
RP   INTERACTION WITH EXOC2, AND SUBCELLULAR LOCATION.
RX   PubMed=17018283; DOI=10.1016/j.cell.2006.08.034;
RA   Chien Y., Kim S., Bumeister R., Loo Y.M., Kwon S.W., Johnson C.L.,
RA   Balakireva M.G., Romeo Y., Kopelovich L., Gale M. Jr., Yeaman C.,
RA   Camonis J.H., Zhao Y., White M.A.;
RT   "RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples
RT   innate immune signaling to tumor cell survival.";
RL   Cell 127:157-170(2006).
RN   [20]
RP   DOMAIN.
RX   PubMed=17599067; DOI=10.1038/sj.emboj.7601773;
RA   Ikeda F., Hecker C.M., Rozenknop A., Nordmeier R.D., Rogov V., Hofmann K.,
RA   Akira S., Dotsch V., Dikic I.;
RT   "Involvement of the ubiquitin-like domain of TBK1/IKK-i kinases in
RT   regulation of IFN-inducible genes.";
RL   EMBO J. 26:3451-3462(2007).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF DDX3X, AND CATALYTIC ACTIVITY.
RX   PubMed=18583960; DOI=10.1038/emboj.2008.126;
RA   Soulat D., Burckstummer T., Westermayer S., Goncalves A., Bauch A.,
RA   Stefanovic A., Hantschel O., Bennett K.L., Decker T., Superti-Furga G.;
RT   "The DEAD-box helicase DDX3X is a critical component of the TANK-binding
RT   kinase 1-dependent innate immune response.";
RL   EMBO J. 27:2135-2146(2008).
RN   [22]
RP   INTERACTION WITH CYLD.
RX   PubMed=18636086; DOI=10.1038/embor.2008.136;
RA   Friedman C.S., O'Donnell M.A., Legarda-Addison D., Ng A., Cardenas W.B.,
RA   Yount J.S., Moran T.M., Basler C.F., Komuro A., Horvath C.M., Xavier R.,
RA   Ting A.T.;
RT   "The tumour suppressor CYLD is a negative regulator of RIG-I-mediated
RT   antiviral response.";
RL   EMBO Rep. 9:930-936(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   INTERACTION WITH SRC.
RX   PubMed=19419966; DOI=10.1074/jbc.m808233200;
RA   Johnsen I.B., Nguyen T.T., Bergstroem B., Fitzgerald K.A., Anthonsen M.W.;
RT   "The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible gene I)-
RT   elicited antiviral signaling.";
RL   J. Biol. Chem. 284:19122-19131(2009).
RN   [25]
RP   INTERACTION WITH EBOLAVIRUS PROTEIN VP35, AND AUTOPHOSPHORYLATION.
RX   PubMed=19153231; DOI=10.1128/jvi.01875-08;
RA   Prins K.C., Cardenas W.B., Basler C.F.;
RT   "Ebola virus protein VP35 impairs the function of interferon regulatory
RT   factor-activating kinases IKKepsilon and TBK-1.";
RL   J. Virol. 83:3069-3077(2009).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   UBIQUITINATION BY NRDP1.
RX   PubMed=19483718; DOI=10.1038/ni.1742;
RA   Wang C., Chen T., Zhang J., Yang M., Li N., Xu X., Cao X.;
RT   "The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated
RT   production of type I interferon.";
RL   Nat. Immunol. 10:744-752(2009).
RN   [28]
RP   INTERACTION WITH STING1.
RX   PubMed=19416887; DOI=10.1073/pnas.0900818106;
RA   Li Y., Li C., Xue P., Zhong B., Mao A.P., Ran Y., Chen H., Wang Y.Y.,
RA   Yang F., Shu H.B.;
RT   "ISG56 is a negative-feedback regulator of virus-triggered signaling and
RT   cellular antiviral response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:7945-7950(2009).
RN   [29]
RP   INTERACTION WITH HSP90AA1.
RX   PubMed=20628368; DOI=10.1038/cr.2010.103;
RA   Liu X.Y., Wei B., Shi H.X., Shan Y.F., Wang C.;
RT   "Tom70 mediates activation of interferon regulatory factor 3 on
RT   mitochondria.";
RL   Cell Res. 20:994-1011(2010).
RN   [30]
RP   AUTOPHOSPHORYLATION, SUBUNIT, AND INTERACTION WITH GSK3B.
RX   PubMed=21145761; DOI=10.1016/j.immuni.2010.11.021;
RA   Lei C.Q., Zhong B., Zhang Y., Zhang J., Wang S., Shu H.B.;
RT   "Glycogen synthase kinase 3beta regulates IRF3 transcription factor-
RT   mediated antiviral response via activation of the kinase TBK1.";
RL   Immunity 33:878-889(2010).
RN   [31]
RP   INTERACTION WITH DDX3X.
RX   PubMed=20375222; DOI=10.1099/vir.0.020552-0;
RA   Yu S., Chen J., Wu M., Chen H., Kato N., Yuan Z.;
RT   "Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-
RT   mediated beta interferon induction in human hepatocytes through
RT   interference with interferon regulatory factor 3 activation and dampening
RT   of the interaction between TBK1/IKKepsilon and DDX3.";
RL   J. Gen. Virol. 91:2080-2090(2010).
RN   [32]
RP   INTERACTION WITH OPTN AND TRAF3.
RX   PubMed=20174559; DOI=10.1371/journal.ppat.1000778;
RA   Mankouri J., Fragkoudis R., Richards K.H., Wetherill L.F., Harris M.,
RA   Kohl A., Elliott R.M., Macdonald A.;
RT   "Optineurin negatively regulates the induction of IFNbeta in response to
RT   RNA virus infection.";
RL   PLoS Pathog. 6:E1000778-E1000778(2010).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   INVOLVEMENT IN GLC1P, TISSUE SPECIFICITY, AND VARIANTS PHE-151; ILE-306 AND
RP   ALA-464.
RX   PubMed=21447600; DOI=10.1093/hmg/ddr123;
RA   Fingert J.H., Robin A.L., Stone J.L., Roos B.R., Davis L.K., Scheetz T.E.,
RA   Bennett S.R., Wassink T.H., Kwon Y.H., Alward W.L., Mullins R.F.,
RA   Sheffield V.C., Stone E.M.;
RT   "Copy number variations on chromosome 12q14 in patients with normal tension
RT   glaucoma.";
RL   Hum. Mol. Genet. 20:2482-2494(2011).
RN   [35]
RP   UBIQUITINATION BY MIB1.
RX   PubMed=21903422; DOI=10.1016/j.immuni.2011.06.014;
RA   Li S., Wang L., Berman M., Kong Y.Y., Dorf M.E.;
RT   "Mapping a dynamic innate immunity protein interaction network regulating
RT   type I interferon production.";
RL   Immunity 35:426-440(2011).
RN   [36]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH IFIT3 AND MAVS.
RX   PubMed=21813773; DOI=10.4049/jimmunol.1100963;
RA   Liu X.Y., Chen W., Wei B., Shan Y.F., Wang C.;
RT   "IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging
RT   MAVS and TBK1.";
RL   J. Immunol. 187:2559-2568(2011).
RN   [37]
RP   FUNCTION IN PHOSPHORYLATION OF VPS37C, AND CATALYTIC ACTIVITY.
RX   PubMed=21270402; DOI=10.4049/jimmunol.1000262;
RA   Da Q., Yang X., Xu Y., Gao G., Cheng G., Tang H.;
RT   "TANK-binding kinase 1 attenuates PTAP-dependent retroviral budding through
RT   targeting endosomal sorting complex required for transport-I.";
RL   J. Immunol. 186:3023-3030(2011).
RN   [38]
RP   FUNCTION, INTERACTION WITH AZI2; TANK AND TBKBP1, AND MUTAGENESIS OF
RP   ASP-135; MET-690; LEU-693; LYS-694; LEU-704; ASN-708 AND LEU-711.
RX   PubMed=21931631; DOI=10.1371/journal.pone.0023971;
RA   Goncalves A., Burckstummer T., Dixit E., Scheicher R., Gorna M.W.,
RA   Karayel E., Sugar C., Stukalov A., Berg T., Kralovics R., Planyavsky M.,
RA   Bennett K.L., Colinge J., Superti-Furga G.;
RT   "Functional dissection of the TBK1 molecular network.";
RL   PLoS ONE 6:E23971-E23971(2011).
RN   [39]
RP   FUNCTION IN PHOSPHORYLATION OF AKT1, AND CATALYTIC ACTIVITY.
RX   PubMed=21464307; DOI=10.1073/pnas.1016132108;
RA   Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y.,
RA   Guan K.L.;
RT   "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct
RT   phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011).
RN   [40]
RP   FUNCTION IN PHOSPHORYLATION OF OPTN, AND CATALYTIC ACTIVITY.
RX   PubMed=21617041; DOI=10.1126/science.1205405;
RA   Wild P., Farhan H., McEwan D.G., Wagner S., Rogov V.V., Brady N.R.,
RA   Richter B., Korac J., Waidmann O., Choudhary C., Dotsch V., Bumann D.,
RA   Dikic I.;
RT   "Phosphorylation of the autophagy receptor optineurin restricts Salmonella
RT   growth.";
RL   Science 333:228-233(2011).
RN   [41]
RP   REVIEW ON FUNCTION, AND DOMAIN.
RX   PubMed=21042276; DOI=10.1038/onc.2010.493;
RA   Shen R.R., Hahn W.C.;
RT   "Emerging roles for the non-canonical IKKs in cancer.";
RL   Oncogene 30:631-641(2011).
RN   [42]
RP   FUNCTION, AND PHOSPHORYLATION BY IKBKB/IKKB.
RX   PubMed=21138416; DOI=10.1042/bj20101701;
RA   Clark K., Peggie M., Plater L., Sorcek R.J., Young E.R., Madwed J.B.,
RA   Hough J., McIver E.G., Cohen P.;
RT   "Novel cross-talk within the IKK family controls innate immunity.";
RL   Biochem. J. 434:93-104(2011).
RN   [43]
RP   DEPHOSPHORYLATION AT SER-172.
RX   PubMed=22750291; DOI=10.1016/j.cellsig.2012.06.017;
RA   Zhao Y., Liang L., Fan Y., Sun S., An L., Shi Z., Cheng J., Jia W., Sun W.,
RA   Mori-Akiyama Y., Zhang H., Fu S., Yang J.;
RT   "PPM1B negatively regulates antiviral response via dephosphorylating
RT   TBK1.";
RL   Cell. Signal. 24:2197-2204(2012).
RN   [44]
RP   INVOLVEMENT IN GLC1P.
RX   PubMed=22306015; DOI=10.1016/j.exer.2011.12.021;
RA   Kawase K., Allingham R.R., Meguro A., Mizuki N., Roos B.,
RA   Solivan-Timpe F.M., Robin A.L., Ritch R., Fingert J.H.;
RT   "Confirmation of TBK1 duplication in normal tension glaucoma.";
RL   Exp. Eye Res. 96:178-180(2012).
RN   [45]
RP   INVOLVEMENT IN IIAE8, VARIANTS IIAE8 ALA-50 AND ALA-159, CHARACTERIZATION
RP   OF VARIANTS IIAE8 ALA-50 AND ALA-159, MUTAGENESIS OF LYS-38,
RP   PHOSPHORYLATION AT SER-172, AND FUNCTION.
RX   PubMed=22851595; DOI=10.1084/jem.20111316;
RA   Herman M., Ciancanelli M., Ou Y.H., Lorenzo L., Klaudel-Dreszler M.,
RA   Pauwels E., Sancho-Shimizu V., Perez de Diego R., Abhyankar A.,
RA   Israelsson E., Guo Y., Cardon A., Rozenberg F., Lebon P., Tardieu M.,
RA   Heropolitanska-Pliszka E., Chaussabel D., White M.A., Abel L., Zhang S.Y.,
RA   Casanova J.L.;
RT   "Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes
RT   simplex encephalitis of childhood.";
RL   J. Exp. Med. 209:1567-1582(2012).
RN   [46]
RP   UBIQUITINATION BY TRAIP.
RX   PubMed=22945920; DOI=10.1084/jem.20120024;
RA   Zhang M., Wang L., Zhao X., Zhao K., Meng H., Zhao W., Gao C.;
RT   "TRAF-interacting protein (TRIP) negatively regulates IFN-beta production
RT   and antiviral response by promoting proteasomal degradation of TANK-binding
RT   kinase 1.";
RL   J. Exp. Med. 209:1703-1711(2012).
RN   [47]
RP   UBIQUITINATION AT LYS-670 BY DTX4.
RX   PubMed=22388039; DOI=10.1038/ni.2239;
RA   Cui J., Li Y., Zhu L., Liu D., Songyang Z., Wang H.Y., Wang R.F.;
RT   "NLRP4 negatively regulates type I interferon signaling by targeting the
RT   kinase TBK1 for degradation via the ubiquitin ligase DTX4.";
RL   Nat. Immunol. 13:387-395(2012).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-716, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [49]
RP   INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION).
RX   PubMed=24478431; DOI=10.1128/jvi.03021-13;
RA   Santiago F.W., Covaleda L.M., Sanchez-Aparicio M.T., Silvas J.A.,
RA   Diaz-Vizarreta A.C., Patel J.R., Popov V., Yu X.J., Garcia-Sastre A.,
RA   Aguilar P.V.;
RT   "Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic
RT   structures correlates with the inhibition of type I interferon responses.";
RL   J. Virol. 88:4572-4585(2014).
RN   [50]
RP   INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION).
RX   PubMed=24706939; DOI=10.1093/jmcb/mju015;
RA   Ning Y.J., Wang M., Deng M., Shen S., Liu W., Cao W.C., Deng F., Wang Y.Y.,
RA   Hu Z., Wang H.;
RT   "Viral suppression of innate immunity via spatial isolation of
RT   TBK1/IKKepsilon from mitochondrial antiviral platform.";
RL   J. Mol. Cell Biol. 6:324-337(2014).
RN   [51]
RP   INVOLVEMENT IN FTDALS4, AND VARIANTS FTDALS4 ILE-306; GLU-401 AND LYS-696.
RX   PubMed=25943890; DOI=10.1007/s00401-015-1436-x;
RA   Pottier C., Bieniek K.F., Finch N., van de Vorst M., Baker M.,
RA   Perkersen R., Brown P., Ravenscroft T., van Blitterswijk M.,
RA   Nicholson A.M., DeTure M., Knopman D.S., Josephs K.A., Parisi J.E.,
RA   Petersen R.C., Boylan K.B., Boeve B.F., Graff-Radford N.R., Veltman J.A.,
RA   Gilissen C., Murray M.E., Dickson D.W., Rademakers R.;
RT   "Whole-genome sequencing reveals important role for TBK1 and OPTN mutations
RT   in frontotemporal lobar degeneration without motor neuron disease.";
RL   Acta Neuropathol. 130:77-92(2015).
RN   [52]
RP   INTERACTION WITH TICAM1.
RX   PubMed=25736436; DOI=10.15252/embr.201439637;
RA   Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B.,
RA   Liu Y.;
RT   "WDFY1 mediates TLR3/4 signaling by recruiting TRIF.";
RL   EMBO Rep. 16:447-455(2015).
RN   [53]
RP   INVOLVEMENT IN IIAE8, AND VARIANT IIAE8 VAL-207.
RX   PubMed=26513235; DOI=10.1038/gene.2015.46;
RA   Moerk N., Kofod-Olsen E., Soerensen K.B., Bach E., Oerntoft T.F.,
RA   Oestergaard L., Paludan S.R., Christiansen M., Mogensen T.H.;
RT   "Mutations in the TLR3 signaling pathway and beyond in adult patients with
RT   herpes simplex encephalitis.";
RL   Genes Immun. 16:552-566(2015).
RN   [54]
RP   INVOLVEMENT IN FTDALS4, VARIANTS FTDALS4 HIS-47; CYS-105; THR-305; GLN-308;
RP   GLN-357; ARG-559; VAL-571; VAL-598; GLU-643 DEL AND LYS-696, AND
RP   CHARACTERIZATION OF VARIANTS FTDALS4 HIS-47; GLN-308; GLN-357; ARG-559 AND
RP   LYS-696.
RX   PubMed=25803835; DOI=10.1038/nn.4000;
RA   Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., Mueller K.,
RA   Marroquin N., Nordin F., Huebers A., Weydt P., Pinto S., Press R.,
RA   Millecamps S., Molko N., Bernard E., Desnuelle C., Soriani M.H., Dorst J.,
RA   Graf E., Nordstroem U., Feiler M.S., Putz S., Boeckers T.M., Meyer T.,
RA   Winkler A.S., Winkelman J., de Carvalho M., Thal D.R., Otto M.,
RA   Braennstroem T., Volk A.E., Kursula P., Danzer K.M., Lichtner P., Dikic I.,
RA   Meitinger T., Ludolph A.C., Strom T.M., Andersen P.M., Weishaupt J.H.;
RT   "Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal
RT   dementia.";
RL   Nat. Neurosci. 18:631-636(2015).
RN   [55]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=25636800; DOI=10.1126/science.aaa2630;
RA   Liu S., Cai X., Wu J., Cong Q., Chen X., Li T., Du F., Ren J., Wu Y.T.,
RA   Grishin N.V., Chen Z.J.;
RT   "Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF
RT   induces IRF3 activation.";
RL   Science 347:AAA2630-AAA2630(2015).
RN   [56]
RP   FUNCTION.
RX   PubMed=27103069; DOI=10.15252/embj.201593350;
RA   Sellier C., Campanari M.L., Julie Corbier C., Gaucherot A.,
RA   Kolb-Cheynel I., Oulad-Abdelghani M., Ruffenach F., Page A., Ciura S.,
RA   Kabashi E., Charlet-Berguerand N.;
RT   "Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to
RT   induce motor neuron dysfunction and cell death.";
RL   EMBO J. 35:1276-1297(2016).
RN   [57]
RP   INTERACTION WITH TRIM26, AND FUNCTION.
RX   PubMed=26611359; DOI=10.1093/jmcb/mjv068;
RA   Ran Y., Zhang J., Liu L.L., Pan Z.Y., Nie Y., Zhang H.Y., Wang Y.Y.;
RT   "Autoubiquitination of TRIM26 links TBK1 to NEMO in RLR-mediated innate
RT   antiviral immune response.";
RL   J. Mol. Cell Biol. 8:31-43(2016).
RN   [58]
RP   UBIQUITINATION BY RNF128.
RX   PubMed=27776110; DOI=10.1038/ni.3588;
RA   Song G., Liu B., Li Z., Wu H., Wang P., Zhao K., Jiang G., Zhang L.,
RA   Gao C.;
RT   "E3 ubiquitin ligase RNF128 promotes innate antiviral immunity through K63-
RT   linked ubiquitination of TBK1.";
RL   Nat. Immunol. 17:1342-1351(2016).
RN   [59]
RP   INTERACTION WITH TTLL12 AND MAVS.
RX   PubMed=28011935; DOI=10.4049/jimmunol.1601194;
RA   Ju L.G., Zhu Y., Lei P.J., Yan D., Zhu K., Wang X., Li Q.L., Li X.J.,
RA   Chen J.W., Li L.Y., Wu M.;
RT   "TTLL12 Inhibits the Activation of Cellular Antiviral Signaling through
RT   Interaction with VISA/MAVS.";
RL   J. Immunol. 198:1274-1284(2017).
RN   [60]
RP   INTERACTION WITH HEARTLAND VIRUS NSS (MICROBIAL INFECTION).
RX   PubMed=28848048; DOI=10.1074/jbc.m117.805127;
RA   Ning Y.J., Feng K., Min Y.Q., Deng F., Hu Z., Wang H.;
RT   "Heartland virus NSs protein disrupts host defenses by blocking the TBK1
RT   kinase-IRF3 transcription factor interaction and signaling required for
RT   interferon induction.";
RL   J. Biol. Chem. 292:16722-16733(2017).
RN   [61]
RP   INTERACTION WITH HEARTLAND VIRUS NSS (MICROBIAL INFECTION), INTERACTION
RP   WITH SFTSV NSS (MICROBIAL INFECTION), AND PHOSPHORYLATION AT SER-172.
RX   PubMed=28680969; DOI=10.1128/msphere.00234-17;
RA   Rezelj V.V., Li P., Chaudhary V., Elliott R.M., Jin D.Y., Brennan B.;
RT   "Differential Antagonism of Human Innate Immune Responses by Tick-Borne
RT   Phlebovirus Nonstructural Proteins.";
RL   MSphere 2:0-0(2017).
RN   [62]
RP   INTERACTION WITH TRIM23.
RX   PubMed=28871090; DOI=10.1038/s41564-017-0017-2;
RA   Sparrer K.M.J., Gableske S., Zurenski M.A., Parker Z.M., Full F.,
RA   Baumgart G.J., Kato J., Pacheco-Rodriguez G., Liang C., Pornillos O.,
RA   Moss J., Vaughan M., Gack M.U.;
RT   "TRIM23 mediates virus-induced autophagy via activation of TBK1.";
RL   Nat. Microbiol. 2:1543-1557(2017).
RN   [63]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 PROTEIN ICP34.5 (MICROBIAL
RP   INFECTION).
RX   PubMed=28904192; DOI=10.1128/jvi.01156-17;
RA   Manivanh R., Mehrbach J., Knipe D.M., Leib D.A.;
RT   "Role of Herpes Simplex Virus 1 gamma34.5 in the Regulation of IRF3
RT   Signaling.";
RL   J. Virol. 91:0-0(2017).
RN   [64]
RP   INTERACTION WITH ZIKA VIRUS NON-STRUCTURAL PROTEIN 1 AND NON-STRUCTURAL
RP   PROTEIN 4B (MICROBIAL INFECTION).
RX   PubMed=28373913; DOI=10.1038/celldisc.2017.6;
RA   Wu Y., Liu Q., Zhou J., Xie W., Chen C., Wang Z., Yang H., Cui J.;
RT   "Zika virus evades interferon-mediated antiviral response through the co-
RT   operation of multiple nonstructural proteins in vitro.";
RL   Cell Discov. 3:17006-17006(2017).
RN   [65]
RP   INTERACTION WITH CEP170.
RX   PubMed=30354798; DOI=10.1091/mbc.e18-02-0115;
RA   Baerenz F., Kschonsak Y.T., Meyer A., Jafarpour A., Lorenz H., Hoffmann I.;
RT   "Ccdc61 controls centrosomal localization of Cep170 and is required for
RT   spindle assembly and symmetry.";
RL   Mol. Biol. Cell 29:3105-3118(2018).
RN   [66]
RP   INTERACTION WITH TTC4; IKBKE; AZI2 AND TANK, AND SUBCELLULAR LOCATION.
RX   PubMed=29251827; DOI=10.1002/pmic.201700403;
RA   Shang J., Xia T., Han Q.Q., Zhao X., Hu M.M., Shu H.B., Guo L.;
RT   "Quantitative Proteomics Identified TTC4 as a TBK1 Interactor and a
RT   Positive Regulator of SeV-Induced Innate Immunity.";
RL   Proteomics 18:0-0(2018).
RN   [67]
RP   INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION).
RX   PubMed=30021900; DOI=10.1128/jvi.00706-18;
RA   Moriyama M., Igarashi M., Koshiba T., Irie T., Takada A., Ichinohe T.;
RT   "Two Conserved Amino Acids within the NSs of Severe Fever with
RT   Thrombocytopenia Syndrome Phlebovirus Are Essential for Anti-interferon
RT   Activity.";
RL   J. Virol. 92:0-0(2018).
RN   [68]
RP   INTERACTION WITH HNRNPA2B1.
RX   PubMed=31320558; DOI=10.1126/science.aav0758;
RA   Wang L., Wen M., Cao X.;
RT   "Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to
RT   DNA viruses.";
RL   Science 0:0-0(2019).
RN   [69]
RP   INTERACTION WITH CYLD.
RX   PubMed=32185393; DOI=10.1093/brain/awaa039;
RA   Dobson-Stone C., Hallupp M., Shahheydari H., Ragagnin A.M.G.,
RA   Chatterton Z., Carew-Jones F., Shepherd C.E., Stefen H., Paric E., Fath T.,
RA   Thompson E.M., Blumbergs P., Short C.L., Field C.D., Panegyres P.K.,
RA   Hecker J., Nicholson G., Shaw A.D., Fullerton J.M., Luty A.A.,
RA   Schofield P.R., Brooks W.S., Rajan N., Bennett M.F., Bahlo M.,
RA   Landers J.E., Piguet O., Hodges J.R., Halliday G.M., Topp S.D., Smith B.N.,
RA   Shaw C.E., McCann E., Fifita J.A., Williams K.L., Atkin J.D., Blair I.P.,
RA   Kwok J.B.;
RT   "CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral
RT   sclerosis.";
RL   Brain 143:783-799(2020).
RN   [70]
RP   INTERACTION WITH SARS-COV-2 NON-STRUCTURAL PROTEIN 6 (MICROBIAL INFECTION),
RP   AND INTERACTION WITH SARS-COV-2 HELICASE (MICROBIAL INFECTION).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   "Evasion of Type I Interferon by SARS-CoV-2.";
RL   Cell Rep. 33:108234-108234(2020).
RN   [71]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38.
RX   PubMed=31709703; DOI=10.15252/embr.201948317;
RA   Herhaus L., Bhaskara R.M., Lystad A.H., Gestal-Mato U.,
RA   Covarrubias-Pinto A., Bonn F., Simonsen A., Hummer G., Dikic I.;
RT   "TBK1-mediated phosphorylation of LC3C and GABARAP-L2 controls
RT   autophagosome shedding by ATG4 protease.";
RL   EMBO Rep. 21:e48317-e48317(2020).
RN   [72]
RP   INTERACTION WITH TRIM14, AND FUNCTION.
RX   PubMed=32404352; DOI=10.4049/jimmunol.1901511;
RA   Hoffpauir C.T., Bell S.L., West K.O., Jing T., Wagner A.R., Torres-Odio S.,
RA   Cox J.S., West A.P., Li P., Patrick K.L., Watson R.O.;
RT   "TRIM14 Is a Key Regulator of the Type I IFN Response during Mycobacterium
RT   tuberculosis Infection.";
RL   J. Immunol. 205:153-167(2020).
RN   [73]
RP   INTERACTION WITH TRAF3IP3, AND UBIQUITINATION.
RX   PubMed=32366851; DOI=10.1038/s41467-020-16014-0;
RA   Deng M., Tam J.W., Wang L., Liang K., Li S., Zhang L., Guo H., Luo X.,
RA   Zhang Y., Petrucelli A., Davis B.K., Conti B.J., June Brickey W., Ko C.C.,
RA   Lei Y.L., Sun S., Ting J.P.;
RT   "TRAF3IP3 negatively regulates cytosolic RNA induced anti-viral signaling
RT   by promoting TBK1 K48 ubiquitination.";
RL   Nat. Commun. 11:2193-2193(2020).
RN   [74]
RP   INTERACTION WITH SARS-COV-2 M PROTEIN (MICROBIAL INFECTION), FUNCTION, AND
RP   UBIQUITINATION.
RX   PubMed=34084167; DOI=10.3389/fimmu.2021.662989;
RA   Sui L., Zhao Y., Wang W., Wu P., Wang Z., Yu Y., Hou Z., Tan G., Liu Q.;
RT   "SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production Through
RT   Ubiquitin-Mediated Degradation of TBK1.";
RL   Front. Immunol. 12:662989-662989(2021).
RN   [75]
RP   INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL35 (MICROBIAL INFECTION).
RX   PubMed=32466380; DOI=10.3390/microorganisms8060790;
RA   Fabits M., Goncalves Magalhaes V., Chan B., Girault V., Elbasani E.,
RA   Rossetti E., Saeland E., Messerle M., Pichlmair A., Lisnic V.J.,
RA   Brinkmann M.M.;
RT   "The Cytomegalovirus Tegument Protein UL35 Antagonizes Pattern Recognition
RT   Receptor-Mediated Type I IFN Transcription.";
RL   Microorganisms 8:0-0(2020).
RN   [76]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS,
RP   FUNCTION, ACTIVE SITE, HOMODIMER, UBIQUITINATION AT LYS-30 AND LYS-401, AND
RP   MUTAGENESIS OF LYS-30; ASP-33; LYS-38; ASP-135; GLU-355; ARG-357; LYS-401;
RP   ARG-547; TYR-577; GLU-580; ILE-582 AND LYS-589.
RX   PubMed=23453971; DOI=10.1016/j.celrep.2013.01.034;
RA   Larabi A., Devos J.M., Ng S.L., Nanao M.H., Round A., Maniatis T.,
RA   Panne D.;
RT   "Crystal structure and mechanism of activation of TANK-binding kinase 1.";
RL   Cell Rep. 3:734-746(2013).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (2.61 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS,
RP   FUNCTION, ACTIVE SITE, AUTOPHOSPHORYLATION, HOMODIMER, INTERACTION WITH
RP   AZI2, AND MUTAGENESIS OF LYS-38; ASP-135; SER-172; LEU-316; TYR-325;
RP   GLU-355; GLU-448; HIS-459; ILE-466 AND PHE-470.
RX   PubMed=23453972; DOI=10.1016/j.celrep.2013.01.033;
RA   Tu D., Zhu Z., Zhou A.Y., Yun C.H., Lee K.E., Toms A.V., Li Y., Dunn G.P.,
RA   Chan E., Thai T., Yang S., Ficarro S.B., Marto J.A., Jeon H., Hahn W.C.,
RA   Barbie D.A., Eck M.J.;
RT   "Structure and ubiquitination-dependent activation of TANK-binding kinase
RT   1.";
RL   Cell Rep. 3:747-758(2013).
RN   [78]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS,
RP   FUNCTION, AND PHOSPHORYLATION AT SER-172.
RX   PubMed=23746807; DOI=10.1016/j.str.2013.04.025;
RA   Shu C., Sankaran B., Chaton C.T., Herr A.B., Mishra A., Peng J., Li P.;
RT   "Structural insights into the functions of TBK1 in innate antimicrobial
RT   immunity.";
RL   Structure 21:1137-1148(2013).
RN   [79]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF 1-729 OF MUTANT ASN-135
RP   IN COMPLEX WITH STING1, FUNCTION, INTERACTION WITH STING1, ACTIVE SITE, AND
RP   MUTAGENESIS OF TYR-577; ASN-578 AND GLN-581.
RX   PubMed=30842653; DOI=10.1038/s41586-019-1000-2;
RA   Zhang C., Shang G., Gui X., Zhang X., Bai X.C., Chen Z.J.;
RT   "Structural basis of STING binding with and phosphorylation by TBK1.";
RL   Nature 567:394-398(2019).
RN   [80]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-271; GLU-291; HIS-296; ARG-410 AND
RP   ALA-464.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [81]
RP   VARIANTS SER-24; LEU-152; ALA-159; 308-ARG--LEU-729 DEL; GLN-384; SER-388;
RP   THR-397; ILE-508; MET-522; THR-533; GLN-653 AND SER-659, CHARACTERIZATION
RP   OF VARIANTS SER-24; LEU-152; ALA-159; 308-ARG--LEU-729 DEL; GLN-384;
RP   SER-388; THR-397; ILE-508; MET-522; THR-533; GLN-653 AND SER-659, AND
RP   FUNCTION.
RX   PubMed=32972995; DOI=10.1126/science.abd4570;
RG   COVID-STORM Clinicians;
RG   COVID Clinicians;
RG   Imagine COVID Group;
RG   French COVID Cohort Study Group;
RG   CoV-Contact Cohort;
RG   Amsterdam UMC Covid-19 Biobank;
RG   COVID Human Genetic Effort;
RG   NIAID-USUHS/TAGC COVID Immunity Group;
RA   Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J.,
RA   Ogishi M., Sabli I.K.D., Hodeib S., Korol C., Rosain J., Bilguvar K.,
RA   Ye J., Bolze A., Bigio B., Yang R., Arias A.A., Zhou Q., Zhang Y.,
RA   Onodi F., Korniotis S., Karpf L., Philippot Q., Chbihi M., Bonnet-Madin L.,
RA   Dorgham K., Smith N., Schneider W.M., Razooky B.S., Hoffmann H.H.,
RA   Michailidis E., Moens L., Han J.E., Lorenzo L., Bizien L., Meade P.,
RA   Neehus A.L., Ugurbil A.C., Corneau A., Kerner G., Zhang P., Rapaport F.,
RA   Seeleuthner Y., Manry J., Masson C., Schmitt Y., Schlueter A., Le Voyer T.,
RA   Khan T., Li J., Fellay J., Roussel L., Shahrooei M., Alosaimi M.F.,
RA   Mansouri D., Al-Saud H., Al-Mulla F., Almourfi F., Al-Muhsen S.Z.,
RA   Alsohime F., Al Turki S., Hasanato R., van de Beek D., Biondi A.,
RA   Bettini L.R., D'Angio' M., Bonfanti P., Imberti L., Sottini A., Paghera S.,
RA   Quiros-Roldan E., Rossi C., Oler A.J., Tompkins M.F., Alba C.,
RA   Vandernoot I., Goffard J.C., Smits G., Migeotte I., Haerynck F.,
RA   Soler-Palacin P., Martin-Nalda A., Colobran R., Morange P.E., Keles S.,
RA   Coelkesen F., Ozcelik T., Yasar K.K., Senoglu S., Karabela S.N.,
RA   Rodriguez-Gallego C., Novelli G., Hraiech S., Tandjaoui-Lambiotte Y.,
RA   Duval X., Laouenan C., Snow A.L., Dalgard C.L., Milner J.D., Vinh D.C.,
RA   Mogensen T.H., Marr N., Spaan A.N., Boisson B., Boisson-Dupuis S.,
RA   Bustamante J., Puel A., Ciancanelli M.J., Meyts I., Maniatis T.,
RA   Soumelis V., Amara A., Nussenzweig M., Garcia-Sastre A., Krammer F.,
RA   Pujol A., Duffy D., Lifton R.P., Zhang S.Y., Gorochov G., Beziat V.,
RA   Jouanguy E., Sancho-Shimizu V., Rice C.M., Abel L., Notarangelo L.D.,
RA   Cobat A., Su H.C., Casanova J.L.;
RT   "Inborn errors of type I IFN immunity in patients with life-threatening
RT   COVID-19.";
RL   Science 370:0-0(2020).
CC   -!- FUNCTION: Serine/threonine kinase that plays an essential role in
CC       regulating inflammatory responses to foreign agents (PubMed:12692549,
CC       PubMed:14703513, PubMed:18583960, PubMed:12702806, PubMed:15367631,
CC       PubMed:10581243, PubMed:11839743, PubMed:15485837, PubMed:21138416,
CC       PubMed:25636800, PubMed:23453971, PubMed:23453972, PubMed:23746807,
CC       PubMed:26611359, PubMed:32404352). Following activation of toll-like
CC       receptors by viral or bacterial components, associates with TRAF3 and
CC       TANK and phosphorylates interferon regulatory factors (IRFs) IRF3 and
CC       IRF7 as well as DDX3X (PubMed:12692549, PubMed:14703513,
CC       PubMed:18583960, PubMed:12702806, PubMed:15367631, PubMed:25636800).
CC       This activity allows subsequent homodimerization and nuclear
CC       translocation of the IRFs leading to transcriptional activation of pro-
CC       inflammatory and antiviral genes including IFNA and IFNB
CC       (PubMed:12702806, PubMed:15367631, PubMed:25636800, PubMed:32972995).
CC       In order to establish such an antiviral state, TBK1 form several
CC       different complexes whose composition depends on the type of cell and
CC       cellular stimuli (PubMed:23453971, PubMed:23453972, PubMed:23746807).
CC       Plays a key role in IRF3 activation: acts by first phosphorylating
CC       innate adapter proteins MAVS, STING1 and TICAM1 on their pLxIS motif,
CC       leading to recruitment of IRF3, thereby licensing IRF3 for
CC       phosphorylation by TBK1 (PubMed:25636800, PubMed:30842653).
CC       Phosphorylated IRF3 dissociates from the adapter proteins, dimerizes,
CC       and then enters the nucleus to induce expression of interferons
CC       (PubMed:25636800). Thus, several scaffolding molecules including FADD,
CC       TRADD, MAVS, AZI2, TANK or TBKBP1/SINTBAD can be recruited to the TBK1-
CC       containing-complexes (PubMed:21931631). Under particular conditions,
CC       functions as a NF-kappa-B effector by phosphorylating NF-kappa-B
CC       inhibitor alpha/NFKBIA, IKBKB or RELA to translocate NF-Kappa-B to the
CC       nucleus (PubMed:10783893, PubMed:15489227). Restricts bacterial
CC       proliferation by phosphorylating the autophagy receptor OPTN/Optineurin
CC       on 'Ser-177', thus enhancing LC3 binding affinity and antibacterial
CC       autophagy (PubMed:21617041). Phosphorylates SMCR8 component of the
CC       C9orf72-SMCR8 complex, promoting autophagosome maturation
CC       (PubMed:27103069). Phosphorylates ATG8 proteins MAP1LC3C and GABARAPL2,
CC       thereby preventing their delipidation and premature removal from
CC       nascent autophagosomes (PubMed:31709703). Phosphorylates and activates
CC       AKT1 (PubMed:21464307). Seems to play a role in energy balance
CC       regulation by sustaining a state of chronic, low-grade inflammation in
CC       obesity, wich leads to a negative impact on insulin sensitivity (By
CC       similarity). Attenuates retroviral budding by phosphorylating the
CC       endosomal sorting complex required for transport-I (ESCRT-I) subunit
CC       VPS37C (PubMed:21270402). Phosphorylates Borna disease virus (BDV) P
CC       protein (PubMed:16155125). Plays an essential role in the TLR3- and
CC       IFN-dependent control of herpes virus HSV-1 and HSV-2 infections in the
CC       central nervous system (PubMed:22851595).
CC       {ECO:0000250|UniProtKB:Q9WUN2, ECO:0000269|PubMed:10581243,
CC       ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:11839743,
CC       ECO:0000269|PubMed:12692549, ECO:0000269|PubMed:12702806,
CC       ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:15367631,
CC       ECO:0000269|PubMed:15485837, ECO:0000269|PubMed:15489227,
CC       ECO:0000269|PubMed:16155125, ECO:0000269|PubMed:18583960,
CC       ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402,
CC       ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041,
CC       ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:22851595,
CC       ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972,
CC       ECO:0000269|PubMed:23746807, ECO:0000269|PubMed:25636800,
CC       ECO:0000269|PubMed:26611359, ECO:0000269|PubMed:27103069,
CC       ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31709703,
CC       ECO:0000269|PubMed:32972995}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:14703513,
CC         ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960,
CC         ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402,
CC         ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041,
CC         ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:31709703};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10783893,
CC         ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:15367631,
CC         ECO:0000269|PubMed:18583960, ECO:0000269|PubMed:21138416,
CC         ECO:0000269|PubMed:21270402, ECO:0000269|PubMed:21464307,
CC         ECO:0000269|PubMed:21617041, ECO:0000269|PubMed:25636800};
CC   -!- SUBUNIT: Homodimer (PubMed:21145761). Interacts with DDX3X, TIRAP and
CC       TRAF2 (PubMed:10581243, PubMed:14530355). Part of a ternary complex
CC       consisting of TANK, TRAF2 and TBK1 (PubMed:10581243). Interacts with
CC       AZI2, TANK and TBKBP1; these interactions are mutually exclusive and
CC       mediate TBK1 activation (PubMed:14560022, PubMed:21931631,
CC       PubMed:23453972, PubMed:10581243, PubMed:29251827). Interacts with
CC       GSK3B; this interaction promotes TBK1 self-association and
CC       autophosphorylation (PubMed:21145761). Interacts with SIKE1; SIKE1 is
CC       associated with TBK1 under physiological condition and dissociated from
CC       TBK1 upon viral infection or TLR3 stimulation (PubMed:16281057).
CC       Interacts with IRF3, leading to IRF3 phosphorylation (PubMed:14703513,
CC       PubMed:25636800). Interacts with DDX58/RIG-I (PubMed:16281057).
CC       Interacts with CYLD (PubMed:18636086, PubMed:32185393). Interacts with
CC       OPTN and TRAF3 (PubMed:20174559). Interacts with SRC (PubMed:19419966).
CC       Interacts with the exocyst complex subunit SEC5/EXOC2; this interaction
CC       is sufficient to trigger TBK1 activity (PubMed:17018283). Interacts
CC       with STING1, leading to STING1 phosphorylation (PubMed:19416887,
CC       PubMed:25636800, PubMed:30842653). Interacts with IFIT3 (via N-
CC       terminus) (PubMed:21813773). Interacts with MAVS; interaction only
CC       takes place in the presence of IFIT3 and leads to MAVS phosphorylation
CC       (PubMed:21813773, PubMed:25636800, PubMed:28011935). Interacts (via
CC       protein kinase domain) with TTLL12 (via TTL domain); the interaction
CC       prevents MAVS binding to TBK1 (PubMed:28011935). Interacts with TICAM1;
CC       this interaction is enhanced in the presence of WDFY1 and leads to
CC       TICAM1 phosphorylation (PubMed:14530355, PubMed:14739303,
CC       PubMed:25736436, PubMed:25636800). Interacts with TRIM26
CC       (PubMed:26611359). Interacts with TRIM23 (PubMed:28871090). Interacts
CC       with TTC4 and IKBKE (PubMed:29251827). Interacts with HNRNPA2B1
CC       (PubMed:31320558). Interacts with DDX3X (PubMed:20375222). Interacts
CC       with TRIM14 (PubMed:32404352). Interacts with CEP170; efficient complex
CC       formation may be dependent on the presence of CCDC61 (PubMed:30354798).
CC       Interacts with TRAF3IP3 (PubMed:32366851). Interacts with HSP90AA1; the
CC       interaction mediates TBK1 association with TOMM70 (PubMed:20628368).
CC       {ECO:0000269|PubMed:10581243, ECO:0000269|PubMed:14530355,
CC       ECO:0000269|PubMed:14560022, ECO:0000269|PubMed:14703513,
CC       ECO:0000269|PubMed:14739303, ECO:0000269|PubMed:16281057,
CC       ECO:0000269|PubMed:17018283, ECO:0000269|PubMed:18636086,
CC       ECO:0000269|PubMed:19416887, ECO:0000269|PubMed:19419966,
CC       ECO:0000269|PubMed:20174559, ECO:0000269|PubMed:20375222,
CC       ECO:0000269|PubMed:20628368, ECO:0000269|PubMed:21145761,
CC       ECO:0000269|PubMed:21813773, ECO:0000269|PubMed:21931631,
CC       ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:25636800,
CC       ECO:0000269|PubMed:25736436, ECO:0000269|PubMed:26611359,
CC       ECO:0000269|PubMed:28011935, ECO:0000269|PubMed:28871090,
CC       ECO:0000269|PubMed:29251827, ECO:0000269|PubMed:30354798,
CC       ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31320558,
CC       ECO:0000269|PubMed:32185393, ECO:0000269|PubMed:32366851,
CC       ECO:0000269|PubMed:32404352}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Borna disease virus (BDV)
CC       P protein leading to its phosphorylation.
CC       {ECO:0000269|PubMed:16155125}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Ebola virus protein VP35.
CC       {ECO:0000269|PubMed:19153231}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HCV NS3; this interaction
CC       leads to inhibition of cellular antiviral response by blocking
CC       necessary interactions between the TBK1 and its substrates IRF3 and
CC       IRF7. {ECO:0000269|PubMed:15841462}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus 1
CC       protein ICP34.5. {ECO:0000269|PubMed:28904192}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Zika virus non-structural
CC       protein 1/NS1 and non-structural protein 4B/NS4B.
CC       {ECO:0000269|PubMed:28373913}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV-2 non-structural
CC       protein 6; this interaction decreases IRF3 phosphorylation by 57%,
CC       which leads to reduced IFN-beta (IFNB) production (PubMed:32979938).
CC       Interacts with SARS-CoV-2 helicase; this interaction inhibits TBK1
CC       phosphorylation and decreases IRF3 phosphorylation by 75%, which leads
CC       to reduced IFN-beta production (PubMed:32979938). Interacts with SARS-
CC       CoV-2 M protein; the interaction promotes TBK1 degradation via 'Lys-
CC       48'-linked ubiquitination (PubMed:34084167).
CC       {ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:34084167}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus
CC       protein UL35; this interaction inhibits type I interferon production.
CC       {ECO:0000269|PubMed:32466380}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with heartland virus NSs; this
CC       interaction antagonizes TBK1 phosphorylation and inhibits TBK1-IRF3
CC       interaction and thus the establishment of an antiviral state.
CC       {ECO:0000269|PubMed:28680969, ECO:0000269|PubMed:28848048}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with Severe
CC       fever with thrombocytopenia virus (SFTSV) NSs; this interaction
CC       antagonizes TBK1 phosphorylation and sequesters TBK1 in NSs-induced
CC       cytoplasmic inclusion bodies thereby inhibiting the IFN responses.
CC       {ECO:0000269|PubMed:24478431, ECO:0000269|PubMed:24706939,
CC       ECO:0000269|PubMed:28680969, ECO:0000269|PubMed:30021900}.
CC   -!- INTERACTION:
CC       Q9UHD2; Q9UKV8: AGO2; NbExp=2; IntAct=EBI-356402, EBI-528269;
CC       Q9UHD2; Q7Z3C6: ATG9A; NbExp=2; IntAct=EBI-356402, EBI-727146;
CC       Q9UHD2; Q9H6S1: AZI2; NbExp=7; IntAct=EBI-356402, EBI-359973;
CC       Q9UHD2; Q13137: CALCOCO2; NbExp=7; IntAct=EBI-356402, EBI-739580;
CC       Q9UHD2; Q6DT37: CDC42BPG; NbExp=3; IntAct=EBI-356402, EBI-689124;
CC       Q9UHD2; P08238: HSP90AB1; NbExp=2; IntAct=EBI-356402, EBI-352572;
CC       Q9UHD2; Q9Y6W8: ICOS; NbExp=5; IntAct=EBI-356402, EBI-3922712;
CC       Q9UHD2; Q14164: IKBKE; NbExp=5; IntAct=EBI-356402, EBI-307369;
CC       Q9UHD2; Q9Y6K9: IKBKG; NbExp=4; IntAct=EBI-356402, EBI-81279;
CC       Q9UHD2; Q14653: IRF3; NbExp=10; IntAct=EBI-356402, EBI-2650369;
CC       Q9UHD2; Q92985: IRF7; NbExp=2; IntAct=EBI-356402, EBI-968267;
CC       Q9UHD2; Q7Z434: MAVS; NbExp=6; IntAct=EBI-356402, EBI-995373;
CC       Q9UHD2; Q86YT6: MIB1; NbExp=2; IntAct=EBI-356402, EBI-2129148;
CC       Q9UHD2; Q96AX9: MIB2; NbExp=2; IntAct=EBI-356402, EBI-2130249;
CC       Q9UHD2; Q9NVV4: MTPAP; NbExp=2; IntAct=EBI-356402, EBI-2556166;
CC       Q9UHD2; Q96CV9: OPTN; NbExp=16; IntAct=EBI-356402, EBI-748974;
CC       Q9UHD2; O14730: RIOK3; NbExp=3; IntAct=EBI-356402, EBI-1047061;
CC       Q9UHD2; P42226: STAT6; NbExp=7; IntAct=EBI-356402, EBI-1186478;
CC       Q9UHD2; Q86WV6: STING1; NbExp=9; IntAct=EBI-356402, EBI-2800345;
CC       Q9UHD2; Q92844: TANK; NbExp=13; IntAct=EBI-356402, EBI-356349;
CC       Q9UHD2; A7MCY6: TBKBP1; NbExp=9; IntAct=EBI-356402, EBI-359969;
CC       Q9UHD2; Q8IUC6: TICAM1; NbExp=3; IntAct=EBI-356402, EBI-525995;
CC       Q9UHD2; Q12933: TRAF2; NbExp=7; IntAct=EBI-356402, EBI-355744;
CC       Q9UHD2; Q13114: TRAF3; NbExp=4; IntAct=EBI-356402, EBI-357631;
CC       Q9UHD2; O95801: TTC4; NbExp=5; IntAct=EBI-356402, EBI-1050890;
CC       Q9UHD2; P40222: TXLNA; NbExp=6; IntAct=EBI-356402, EBI-359793;
CC       Q9UHD2; Q62167: Ddx3x; Xeno; NbExp=8; IntAct=EBI-356402, EBI-773173;
CC       Q9UHD2; O41932: GAMMAHV.ORF11; Xeno; NbExp=4; IntAct=EBI-356402, EBI-9544132;
CC       Q9UHD2; P0DTC5: M; Xeno; NbExp=10; IntAct=EBI-356402, EBI-25475853;
CC       Q9UHD2; P59596: M; Xeno; NbExp=5; IntAct=EBI-356402, EBI-25487824;
CC       Q9UHD2; PRO_0000449630 [P0DTD1]: rep; Xeno; NbExp=6; IntAct=EBI-356402, EBI-25475888;
CC       Q9UHD2; Q60803: Traf3; Xeno; NbExp=2; IntAct=EBI-356402, EBI-520135;
CC       Q9UHD2; Q8BHN1: Txlng; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6116854;
CC       Q9UHD2; Q05127: VP35; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6148294;
CC       Q9UHD2; I0DF37; Xeno; NbExp=3; IntAct=EBI-356402, EBI-9543922;
CC       Q9UHD2; I6W9F2; Xeno; NbExp=6; IntAct=EBI-356402, EBI-9518472;
CC       Q9UHD2; K7Y1A2; Xeno; NbExp=2; IntAct=EBI-356402, EBI-8788634;
CC       Q9UHD2; PRO_0000037572 [P27958]; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6919131;
CC       Q9UHD2; PRO_0000037573 [P27958]; Xeno; NbExp=4; IntAct=EBI-356402, EBI-3649474;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15485837,
CC       ECO:0000269|PubMed:21813773, ECO:0000269|PubMed:29251827}. Note=Upon
CC       mitogen stimulation or triggering of the immune system, TBK1 is
CC       recruited to the exocyst by EXOC2. {ECO:0000269|PubMed:17018283}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous with higher expression in testis.
CC       Expressed in the ganglion cells, nerve fiber layer and microvasculature
CC       of the retina. {ECO:0000269|PubMed:10783893,
CC       ECO:0000269|PubMed:21447600}.
CC   -!- DOMAIN: Comprises A N-terminal kinase domain, a ubiquitin-like domain
CC       and a C-terminal coiled-coil region mediating homodimerization.
CC       {ECO:0000269|PubMed:17599067, ECO:0000269|PubMed:21042276}.
CC   -!- PTM: Autophosphorylation at Ser-172 activates the kinase, and is an
CC       essential step for virus-triggered signaling. Phosphorylated by
CC       IKBKB/IKKB at Ser-172. Phosphorylation requires homodimerization and
CC       ubiquitination at Lys-30 and Lys-401. Dephosphorylated at Ser-172 by
CC       PPM1B and this negatively regulates its role in mediating antiviral
CC       response. {ECO:0000269|PubMed:11839743, ECO:0000269|PubMed:21138416,
CC       ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23746807}.
CC   -!- PTM: 'Lys-63'-linked polyubiquitination by MIB1 after RNA virus
CC       infection, or by NRDP1 after LPS stimulation at Lys-30 and Lys-401,
CC       participates in kinase activation. 'Lys-48'-linked polyubiquitination
CC       at Lys-670 by DTX4 leads to proteasomal degradation. 'Lys-48'-linked
CC       polyubiquitination by TRAIP also leads to proteasomal degradation.
CC       'Lys-63'-linked polyubiquitination by RNF128 at Lys-30 and Lys-401
CC       leads to the activation of antiviral responses.
CC       {ECO:0000269|PubMed:22388039, ECO:0000269|PubMed:23453971,
CC       ECO:0000269|PubMed:27776110, ECO:0000269|PubMed:32366851}.
CC   -!- PTM: (Microbial infection) Interaction with SARS-CoV-2 M protein
CC       induces 'Lys-48'-linked ubiquitination which leads to proteasomal
CC       degradation. {ECO:0000269|PubMed:34084167}.
CC   -!- DISEASE: Glaucoma 1, open angle, P (GLC1P) [MIM:177700]: A form of
CC       primary open angle glaucoma (POAG). POAG is characterized by a specific
CC       pattern of optic nerve and visual field defects. The angle of the
CC       anterior chamber of the eye is open, and usually the intraocular
CC       pressure is increased. However, glaucoma can occur at any intraocular
CC       pressure. The disease is generally asymptomatic until the late stages,
CC       by which time significant and irreversible optic nerve damage has
CC       already taken place. GLC1P is characterized by early onset, thin
CC       central corneas and low intraocular pressure.
CC       {ECO:0000269|PubMed:21447600, ECO:0000269|PubMed:22306015}. Note=The
CC       disease may be caused by variants affecting the gene represented in
CC       this entry. A copy number variation on chromosome 12q14 consisting of a
CC       300 kb duplication that includes TBK1, XPOT, RASSF3 and GNS has been
CC       found in individuals affected by glaucoma. TBK1 is the most likely
CC       candidate for the disorder (PubMed:21447600).
CC       {ECO:0000269|PubMed:21447600}.
CC   -!- DISEASE: Frontotemporal dementia and/or amyotrophic lateral sclerosis 4
CC       (FTDALS4) [MIM:616439]: A neurodegenerative disorder characterized by
CC       frontotemporal dementia and/or amyotrophic lateral sclerosis in
CC       affected individuals. There is high intrafamilial variation.
CC       Frontotemporal dementia is characterized by frontal and temporal lobe
CC       atrophy associated with neuronal loss, gliosis, and dementia. Patients
CC       exhibit progressive changes in social, behavioral, and/or language
CC       function. Amyotrophic lateral sclerosis is characterized by the death
CC       of motor neurons in the brain, brainstem, and spinal cord, resulting in
CC       fatal paralysis. {ECO:0000269|PubMed:25803835,
CC       ECO:0000269|PubMed:25943890}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Encephalopathy, acute, infection-induced, 8, herpes-specific
CC       (IIAE8) [MIM:617900]: A rare, often fatal complication of herpes
CC       simplex infection, caused by virus spreading in the central nervous
CC       system. Disease manifestations include low-grade fever, severe
CC       headache, nausea, vomiting, and lethargy. Neurological features include
CC       confusion, acute memory disturbances, disorientation, behavioral
CC       changes, hemiparesis and seizures. {ECO:0000269|PubMed:22851595,
CC       ECO:0000269|PubMed:26513235}. Note=Disease susceptibility is associated
CC       with variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: In cancer cells, pathological TBK1 activation promotes
CC       oncogenic transformation by suppressing programmed cell death.
CC       Mechanistically, the RALB-SEC5/EXOC2-TBK1 signaling cascade seems to
CC       participate in both innate immune signaling and cell transformation.
CC       Additionally, TBK1 supports oncogenesis by directly phosphorylating and
CC       activating AKT1 at the exocyst (PubMed:21042276).
CC       {ECO:0000305|PubMed:21042276}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. I-kappa-B kinase subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92129.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF191838; AAF05989.1; -; mRNA.
DR   EMBL; AF174536; AAF69106.1; -; mRNA.
DR   EMBL; AK002192; BAA92129.1; ALT_INIT; mRNA.
DR   EMBL; AK291039; BAF83728.1; -; mRNA.
DR   EMBL; CH471054; EAW97133.1; -; Genomic_DNA.
DR   EMBL; BC034950; AAH34950.1; -; mRNA.
DR   CCDS; CCDS8968.1; -.
DR   RefSeq; NP_037386.1; NM_013254.3.
DR   RefSeq; XP_005268866.1; XM_005268809.1.
DR   RefSeq; XP_005268867.1; XM_005268810.1.
DR   PDB; 4EFO; X-ray; 1.77 A; A/B=302-383.
DR   PDB; 4EUT; X-ray; 2.60 A; A/B=2-385.
DR   PDB; 4EUU; X-ray; 1.80 A; A/B=2-308.
DR   PDB; 4IM0; X-ray; 2.40 A; A=1-657.
DR   PDB; 4IM2; X-ray; 2.50 A; A=1-657.
DR   PDB; 4IM3; X-ray; 3.34 A; A=1-657.
DR   PDB; 4IW0; X-ray; 4.00 A; A=2-657.
DR   PDB; 4IWO; X-ray; 2.61 A; A=2-657.
DR   PDB; 4IWP; X-ray; 3.06 A; A=2-657.
DR   PDB; 4IWQ; X-ray; 3.00 A; A=2-657.
DR   PDB; 5EOA; X-ray; 2.50 A; C/D=677-729.
DR   PDB; 5EOF; X-ray; 2.05 A; C/D=677-729.
DR   PDB; 5EP6; X-ray; 1.45 A; B/D=677-729.
DR   PDB; 5W5V; X-ray; 3.65 A; A=1-657.
DR   PDB; 6BNY; X-ray; 3.34 A; A=1-657.
DR   PDB; 6BOD; X-ray; 3.20 A; A=1-657.
DR   PDB; 6BOE; X-ray; 3.60 A; A=1-657.
DR   PDB; 6CQ0; X-ray; 3.19 A; A=1-657.
DR   PDB; 6CQ4; X-ray; 3.20 A; A=1-657.
DR   PDB; 6CQ5; X-ray; 3.35 A; A=1-657.
DR   PDB; 6NT9; EM; 3.30 A; A/B=1-729.
DR   PDB; 6O8B; X-ray; 3.40 A; A/B=2-657.
DR   PDB; 6RSR; X-ray; 3.15 A; A=2-657.
DR   PDB; 6RST; X-ray; 3.29 A; A=2-657.
DR   PDB; 6RSU; X-ray; 2.75 A; A=2-657.
DR   PDBsum; 4EFO; -.
DR   PDBsum; 4EUT; -.
DR   PDBsum; 4EUU; -.
DR   PDBsum; 4IM0; -.
DR   PDBsum; 4IM2; -.
DR   PDBsum; 4IM3; -.
DR   PDBsum; 4IW0; -.
DR   PDBsum; 4IWO; -.
DR   PDBsum; 4IWP; -.
DR   PDBsum; 4IWQ; -.
DR   PDBsum; 5EOA; -.
DR   PDBsum; 5EOF; -.
DR   PDBsum; 5EP6; -.
DR   PDBsum; 5W5V; -.
DR   PDBsum; 6BNY; -.
DR   PDBsum; 6BOD; -.
DR   PDBsum; 6BOE; -.
DR   PDBsum; 6CQ0; -.
DR   PDBsum; 6CQ4; -.
DR   PDBsum; 6CQ5; -.
DR   PDBsum; 6NT9; -.
DR   PDBsum; 6O8B; -.
DR   PDBsum; 6RSR; -.
DR   PDBsum; 6RST; -.
DR   PDBsum; 6RSU; -.
DR   AlphaFoldDB; Q9UHD2; -.
DR   SMR; Q9UHD2; -.
DR   BioGRID; 118878; 283.
DR   ComplexPortal; CPX-6018; STING-TRAF3-TBK1 complex.
DR   ComplexPortal; CPX-6038; TBK1-IKKepsilon-NAP1 complex.
DR   ComplexPortal; CPX-6089; TBK1-IKKepsilon-TANK complex.
DR   ComplexPortal; CPX-6090; TBK1-IKKepsilon-SINTBAD complex.
DR   CORUM; Q9UHD2; -.
DR   DIP; DIP-27529N; -.
DR   IntAct; Q9UHD2; 124.
DR   MINT; Q9UHD2; -.
DR   STRING; 9606.ENSP00000329967; -.
DR   BindingDB; Q9UHD2; -.
DR   ChEMBL; CHEMBL5408; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9UHD2; -.
DR   GuidetoPHARMACOLOGY; 2237; -.
DR   iPTMnet; Q9UHD2; -.
DR   MetOSite; Q9UHD2; -.
DR   PhosphoSitePlus; Q9UHD2; -.
DR   BioMuta; TBK1; -.
DR   DMDM; 74761953; -.
DR   CPTAC; CPTAC-910; -.
DR   CPTAC; CPTAC-911; -.
DR   EPD; Q9UHD2; -.
DR   jPOST; Q9UHD2; -.
DR   MassIVE; Q9UHD2; -.
DR   MaxQB; Q9UHD2; -.
DR   PaxDb; Q9UHD2; -.
DR   PeptideAtlas; Q9UHD2; -.
DR   PRIDE; Q9UHD2; -.
DR   ProteomicsDB; 84323; -.
DR   Antibodypedia; 16584; 628 antibodies from 45 providers.
DR   DNASU; 29110; -.
DR   Ensembl; ENST00000331710.10; ENSP00000329967.5; ENSG00000183735.11.
DR   Ensembl; ENST00000650790.1; ENSP00000498995.1; ENSG00000183735.11.
DR   GeneID; 29110; -.
DR   KEGG; hsa:29110; -.
DR   MANE-Select; ENST00000331710.10; ENSP00000329967.5; NM_013254.4; NP_037386.1.
DR   UCSC; uc001ssc.3; human.
DR   CTD; 29110; -.
DR   DisGeNET; 29110; -.
DR   GeneCards; TBK1; -.
DR   HGNC; HGNC:11584; TBK1.
DR   HPA; ENSG00000183735; Low tissue specificity.
DR   MalaCards; TBK1; -.
DR   MIM; 177700; phenotype.
DR   MIM; 604834; gene.
DR   MIM; 616439; phenotype.
DR   MIM; 617900; phenotype.
DR   neXtProt; NX_Q9UHD2; -.
DR   OpenTargets; ENSG00000183735; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   Orphanet; 275872; Frontotemporal dementia with motor neuron disease.
DR   Orphanet; 1930; Herpes simplex virus encephalitis.
DR   PharmGKB; PA36348; -.
DR   VEuPathDB; HostDB:ENSG00000183735; -.
DR   eggNOG; KOG4250; Eukaryota.
DR   GeneTree; ENSGT00950000182937; -.
DR   HOGENOM; CLU_000288_101_1_1; -.
DR   InParanoid; Q9UHD2; -.
DR   OMA; DWSADMP; -.
DR   OrthoDB; 563981at2759; -.
DR   PhylomeDB; Q9UHD2; -.
DR   TreeFam; TF324269; -.
DR   PathwayCommons; Q9UHD2; -.
DR   Reactome; R-HSA-1606341; IRF3 mediated activation of type 1 IFN.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-3134975; Regulation of innate immune responses to cytosolic DNA.
DR   Reactome; R-HSA-3249367; STAT6-mediated induction of chemokines.
DR   Reactome; R-HSA-3270619; IRF3-mediated induction of type I IFN.
DR   Reactome; R-HSA-9008059; Interleukin-37 signaling.
DR   Reactome; R-HSA-9013973; TICAM1-dependent activation of IRF3/IRF7.
DR   Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway.
DR   Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation.
DR   Reactome; R-HSA-936440; Negative regulators of DDX58/IFIH1 signaling.
DR   Reactome; R-HSA-936964; Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   SABIO-RK; Q9UHD2; -.
DR   SignaLink; Q9UHD2; -.
DR   SIGNOR; Q9UHD2; -.
DR   BioGRID-ORCS; 29110; 31 hits in 1124 CRISPR screens.
DR   ChiTaRS; TBK1; human.
DR   GeneWiki; TANK-binding_kinase_1; -.
DR   GenomeRNAi; 29110; -.
DR   Pharos; Q9UHD2; Tchem.
DR   PRO; PR:Q9UHD2; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q9UHD2; protein.
DR   Bgee; ENSG00000183735; Expressed in colonic epithelium and 196 other tissues.
DR   ExpressionAtlas; Q9UHD2; baseline and differential.
DR   Genevisible; Q9UHD2; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:1902554; C:serine/threonine protein kinase complex; IC:ComplexPortal.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:Ensembl.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; NAS:ProtInc.
DR   GO; GO:0019903; F:protein phosphatase binding; ISS:ARUK-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0002218; P:activation of innate immune response; IEA:Ensembl.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IC:ComplexPortal.
DR   GO; GO:0044565; P:dendritic cell proliferation; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; TAS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEP:UniProtKB.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; IDA:BHF-UCL.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; IDA:BHF-UCL.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IDA:HGNC.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; NAS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; TAS:UniProtKB.
DR   GO; GO:0060340; P:positive regulation of type I interferon-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:1904417; P:positive regulation of xenophagy; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1901214; P:regulation of neuron death; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0032479; P:regulation of type I interferon production; IDA:UniProtKB.
DR   GO; GO:0009615; P:response to virus; TAS:UniProtKB.
DR   GO; GO:0060337; P:type I interferon signaling pathway; IC:ComplexPortal.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR041309; TBK1_CCD1.
DR   InterPro; IPR041087; TBK1_ULD.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF18394; TBK1_CCD1; 1.
DR   Pfam; PF18396; TBK1_ULD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amyotrophic lateral sclerosis; Antiviral defense;
KW   ATP-binding; Coiled coil; Cytoplasm; Disease variant; Glaucoma;
KW   Host-virus interaction; Immunity; Innate immunity; Isopeptide bond; Kinase;
KW   Neurodegeneration; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..729
FT                   /note="Serine/threonine-protein kinase TBK1"
FT                   /id="PRO_0000086743"
FT   DOMAIN          9..310
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          309..385
FT                   /note="Ubiquitin-like"
FT   REGION          621..729
FT                   /note="Interaction with AZI2, TANK and TBKBP1"
FT                   /evidence="ECO:0000269|PubMed:21931631"
FT   COILED          407..657
FT                   /evidence="ECO:0000250|UniProtKB:Q9WUN2"
FT   COILED          658..713
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        135
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305|PubMed:23453971,
FT                   ECO:0000305|PubMed:23453972, ECO:0000305|PubMed:30842653"
FT   BINDING         15..23
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         38
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         172
FT                   /note="Phosphoserine; by autocatalysis and IKKB"
FT                   /evidence="ECO:0000269|PubMed:11839743,
FT                   ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23746807"
FT   MOD_RES         716
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        30
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:23453971"
FT   CROSSLNK        401
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:23453971"
FT   CROSSLNK        670
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:22388039"
FT   VARIANT         24
FT                   /note="F -> S (loss of IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084111"
FT   VARIANT         47
FT                   /note="R -> H (in FTDALS4; loss of kinase activity)"
FT                   /evidence="ECO:0000269|PubMed:25803835"
FT                   /id="VAR_073938"
FT   VARIANT         50
FT                   /note="D -> A (in IIAE8; decreased expression levels;
FT                   dbSNP:rs1010930015)"
FT                   /evidence="ECO:0000269|PubMed:22851595"
FT                   /id="VAR_080517"
FT   VARIANT         105
FT                   /note="Y -> C (in FTDALS4; dbSNP:rs1366668789)"
FT                   /evidence="ECO:0000269|PubMed:25803835"
FT                   /id="VAR_073939"
FT   VARIANT         151
FT                   /note="S -> F (in dbSNP:rs55824172)"
FT                   /evidence="ECO:0000269|PubMed:21447600"
FT                   /id="VAR_069754"
FT   VARIANT         152
FT                   /note="V -> L (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084112"
FT   VARIANT         159
FT                   /note="G -> A (in IIAE8; loss of kinase activity; loss of
FT                   autophosphorylation at S-172; loss of IFNB induction;
FT                   dbSNP:rs1555202947)"
FT                   /evidence="ECO:0000269|PubMed:22851595,
FT                   ECO:0000269|PubMed:32972995"
FT                   /id="VAR_080518"
FT   VARIANT         207
FT                   /note="I -> V (in IIAE8; unknown pathological significance;
FT                   dbSNP:rs1555203557)"
FT                   /evidence="ECO:0000269|PubMed:26513235"
FT                   /id="VAR_080519"
FT   VARIANT         271
FT                   /note="R -> Q (in dbSNP:rs56196591)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041208"
FT   VARIANT         291
FT                   /note="K -> E (in dbSNP:rs34774243)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041209"
FT   VARIANT         296
FT                   /note="D -> H (in a breast pleomorphic lobular carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041210"
FT   VARIANT         305
FT                   /note="I -> T (in FTDALS4; dbSNP:rs770942184)"
FT                   /evidence="ECO:0000269|PubMed:25803835"
FT                   /id="VAR_073940"
FT   VARIANT         306
FT                   /note="L -> I (in FTDALS4; unknown pathological
FT                   significance; dbSNP:rs201970436)"
FT                   /evidence="ECO:0000269|PubMed:21447600,
FT                   ECO:0000269|PubMed:25943890"
FT                   /id="VAR_069755"
FT   VARIANT         308..729
FT                   /note="Missing (loss of IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084113"
FT   VARIANT         308
FT                   /note="R -> Q (in FTDALS4; reduced kinase activity)"
FT                   /evidence="ECO:0000269|PubMed:25803835"
FT                   /id="VAR_073941"
FT   VARIANT         357
FT                   /note="R -> Q (in FTDALS4; reduced kinase activity;
FT                   dbSNP:rs758357594)"
FT                   /evidence="ECO:0000269|PubMed:25803835"
FT                   /id="VAR_073942"
FT   VARIANT         384
FT                   /note="R -> Q (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084114"
FT   VARIANT         388
FT                   /note="N -> D (in dbSNP:rs17857028)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_024746"
FT   VARIANT         388
FT                   /note="N -> S (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084115"
FT   VARIANT         397
FT                   /note="I -> T (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084116"
FT   VARIANT         401
FT                   /note="K -> E (in FTDALS4; dbSNP:rs756751089)"
FT                   /evidence="ECO:0000269|PubMed:25943890"
FT                   /id="VAR_073943"
FT   VARIANT         410
FT                   /note="G -> R (in a colorectal adenocarcinoma sample;
FT                   somatic mutation; dbSNP:rs1262765773)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041211"
FT   VARIANT         464
FT                   /note="V -> A (in dbSNP:rs35635889)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:21447600"
FT                   /id="VAR_041212"
FT   VARIANT         508
FT                   /note="L -> I (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084117"
FT   VARIANT         522
FT                   /note="I -> M (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084118"
FT   VARIANT         533
FT                   /note="A -> T (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084119"
FT   VARIANT         559
FT                   /note="M -> R (in FTDALS4; loss of kinase activity)"
FT                   /evidence="ECO:0000269|PubMed:25803835"
FT                   /id="VAR_073944"
FT   VARIANT         570
FT                   /note="K -> Q (in dbSNP:rs17853341)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_024747"
FT   VARIANT         571
FT                   /note="A -> V (in FTDALS4; dbSNP:rs765035140)"
FT                   /evidence="ECO:0000269|PubMed:25803835"
FT                   /id="VAR_073945"
FT   VARIANT         598
FT                   /note="M -> V (in FTDALS4; dbSNP:rs899858451)"
FT                   /evidence="ECO:0000269|PubMed:25803835"
FT                   /id="VAR_073946"
FT   VARIANT         643
FT                   /note="Missing (in FTDALS4)"
FT                   /evidence="ECO:0000269|PubMed:25803835"
FT                   /id="VAR_073947"
FT   VARIANT         653
FT                   /note="E -> Q (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084120"
FT   VARIANT         659
FT                   /note="P -> S (no effect on IFNB induction)"
FT                   /evidence="ECO:0000269|PubMed:32972995"
FT                   /id="VAR_084121"
FT   VARIANT         696
FT                   /note="E -> K (in FTDALS4; loss of kinase activity; impairs
FT                   binding to OPTN; dbSNP:rs748112833)"
FT                   /evidence="ECO:0000269|PubMed:25803835,
FT                   ECO:0000269|PubMed:25943890"
FT                   /id="VAR_073948"
FT   MUTAGEN         30
FT                   /note="K->R: Decreases ubiquitination. Abolishes
FT                   ubiquitination, phosphorylation and kinase activity; when
FT                   associated with R-401."
FT                   /evidence="ECO:0000269|PubMed:23453971"
FT   MUTAGEN         33
FT                   /note="D->A: Decreases phosphorylation and kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:23453971"
FT   MUTAGEN         38
FT                   /note="K->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10581243,
FT                   ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23453971,
FT                   ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:31709703"
FT   MUTAGEN         135
FT                   /note="D->N: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:21931631,
FT                   ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972,
FT                   ECO:0000269|PubMed:30842653"
FT   MUTAGEN         172
FT                   /note="S->A: Loss of kinase activity. No effect on
FT                   dimerization."
FT                   /evidence="ECO:0000269|PubMed:11839743,
FT                   ECO:0000269|PubMed:23453972"
FT   MUTAGEN         172
FT                   /note="S->E: Decreased kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11839743,
FT                   ECO:0000269|PubMed:23453972"
FT   MUTAGEN         316
FT                   /note="L->E: Decreases kinase activity. No effect on
FT                   phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:23453972"
FT   MUTAGEN         325
FT                   /note="Y->E: Abolishes phosphorylation and kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:23453972"
FT   MUTAGEN         355
FT                   /note="E->R: Decreases phosphorylation and kinase activity.
FT                   Abolishes dimerization; when associated with A-357 or
FT                   R-448."
FT                   /evidence="ECO:0000269|PubMed:23453971,
FT                   ECO:0000269|PubMed:23453972"
FT   MUTAGEN         357
FT                   /note="R->A: Decreases phosphorylation and kinase activity.
FT                   Abolishes dimerization; when associated with R-355."
FT                   /evidence="ECO:0000269|PubMed:23453971"
FT   MUTAGEN         401
FT                   /note="K->R: Decreases ubiquitination. Abolishes
FT                   ubiquitination, phosphorylation and kinase activity; when
FT                   associated with R-30."
FT                   /evidence="ECO:0000269|PubMed:23453971"
FT   MUTAGEN         448
FT                   /note="E->R: Decreases phosphorylation and kinase activity.
FT                   Abolishes dimerization; when associated with R-355."
FT                   /evidence="ECO:0000269|PubMed:23453972"
FT   MUTAGEN         459
FT                   /note="H->E: Abolishes dimerization and decreases kinase
FT                   activity but no effect on phosphorylation; when associated
FT                   with E-466 and E-470."
FT                   /evidence="ECO:0000269|PubMed:23453972"
FT   MUTAGEN         466
FT                   /note="I->E: Abolishes dimerization and decreases kinase
FT                   activity but no effect on phosphorylation; when associated
FT                   with E-459 and E-470."
FT                   /evidence="ECO:0000269|PubMed:23453972"
FT   MUTAGEN         470
FT                   /note="F->E: Abolishes dimerization and decreases kinase
FT                   activity but no effect on phosphorylation; when associated
FT                   with E-459 and E-466."
FT                   /evidence="ECO:0000269|PubMed:23453972"
FT   MUTAGEN         547
FT                   /note="R->D: Decreases phosphorylation and kinase activity.
FT                   Abolishes dimerization."
FT                   /evidence="ECO:0000269|PubMed:23453971"
FT   MUTAGEN         577
FT                   /note="Y->A: Decreases kinase activity. Reduced
FT                   phosphorylation of STING1."
FT                   /evidence="ECO:0000269|PubMed:23453971,
FT                   ECO:0000269|PubMed:30842653"
FT   MUTAGEN         578
FT                   /note="N->A: Reduced phosphorylation of STING1."
FT                   /evidence="ECO:0000269|PubMed:30842653"
FT   MUTAGEN         580
FT                   /note="E->A: Decreases kinase activity."
FT                   /evidence="ECO:0000269|PubMed:23453971"
FT   MUTAGEN         581
FT                   /note="Q->A: Reduced phosphorylation of STING1."
FT                   /evidence="ECO:0000269|PubMed:30842653"
FT   MUTAGEN         582
FT                   /note="I->A: Decreases kinase activity."
FT                   /evidence="ECO:0000269|PubMed:23453971"
FT   MUTAGEN         589
FT                   /note="K->D: Decreases phosphorylation and kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:23453971"
FT   MUTAGEN         690
FT                   /note="M->A: Decreases interaction with TANK."
FT                   /evidence="ECO:0000269|PubMed:21931631"
FT   MUTAGEN         693
FT                   /note="L->A: Almost abolishes interaction with TANK."
FT                   /evidence="ECO:0000269|PubMed:21931631"
FT   MUTAGEN         694
FT                   /note="K->E: Strongly decreases interaction with TANK and
FT                   TBKBP1. No effect on phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:21931631"
FT   MUTAGEN         704
FT                   /note="L->A: Strongly decreases interaction with AZI2, TANK
FT                   and TBKBP1. No effect on phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:21931631"
FT   MUTAGEN         708
FT                   /note="N->A: Decreases interaction with TANK."
FT                   /evidence="ECO:0000269|PubMed:21931631"
FT   MUTAGEN         711
FT                   /note="L->A: Almost abolishes interaction with TANK."
FT                   /evidence="ECO:0000269|PubMed:21931631"
FT   STRAND          1..3
FT                   /evidence="ECO:0007829|PDB:6CQ0"
FT   STRAND          5..17
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   STRAND          19..28
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   TURN            29..31
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   STRAND          34..40
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           42..46
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           49..61
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   STRAND          65..67
FT                   /evidence="ECO:0007829|PDB:4IWO"
FT   STRAND          70..75
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   TURN            77..79
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   STRAND          82..87
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           94..99
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           101..103
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           109..128
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           138..140
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   STRAND          141..145
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   STRAND          151..155
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   TURN            161..163
FT                   /evidence="ECO:0007829|PDB:4IWQ"
FT   HELIX           167..169
FT                   /evidence="ECO:0007829|PDB:4EUT"
FT   STRAND          173..175
FT                   /evidence="ECO:0007829|PDB:4EUT"
FT   HELIX           177..179
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           182..188
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           202..216
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   STRAND          220..222
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           227..229
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           231..240
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   STRAND          247..250
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   STRAND          252..254
FT                   /evidence="ECO:0007829|PDB:6NT9"
FT   STRAND          257..262
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           271..284
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   STRAND          285..287
FT                   /evidence="ECO:0007829|PDB:4IWP"
FT   TURN            289..291
FT                   /evidence="ECO:0007829|PDB:4EUU"
FT   HELIX           305..307
FT                   /evidence="ECO:0007829|PDB:4EFO"
FT   STRAND          308..315
FT                   /evidence="ECO:0007829|PDB:4EFO"
FT   TURN            316..319
FT                   /evidence="ECO:0007829|PDB:4EFO"
FT   STRAND          320..327
FT                   /evidence="ECO:0007829|PDB:4EFO"
FT   HELIX           332..343
FT                   /evidence="ECO:0007829|PDB:4EFO"
FT   HELIX           347..349
FT                   /evidence="ECO:0007829|PDB:4EFO"
FT   STRAND          350..354
FT                   /evidence="ECO:0007829|PDB:4EFO"
FT   STRAND          357..359
FT                   /evidence="ECO:0007829|PDB:4EFO"
FT   HELIX           367..369
FT                   /evidence="ECO:0007829|PDB:4EFO"
FT   STRAND          375..377
FT                   /evidence="ECO:0007829|PDB:4IM0"
FT   STRAND          379..383
FT                   /evidence="ECO:0007829|PDB:4EFO"
FT   HELIX           408..480
FT                   /evidence="ECO:0007829|PDB:4IM0"
FT   HELIX           498..526
FT                   /evidence="ECO:0007829|PDB:4IM0"
FT   TURN            527..529
FT                   /evidence="ECO:0007829|PDB:6RSU"
FT   STRAND          530..532
FT                   /evidence="ECO:0007829|PDB:4IWO"
FT   HELIX           535..539
FT                   /evidence="ECO:0007829|PDB:4IM0"
FT   HELIX           544..546
FT                   /evidence="ECO:0007829|PDB:4IM0"
FT   HELIX           548..571
FT                   /evidence="ECO:0007829|PDB:4IM0"
FT   STRAND          572..574
FT                   /evidence="ECO:0007829|PDB:6O8B"
FT   HELIX           577..603
FT                   /evidence="ECO:0007829|PDB:4IM0"
FT   HELIX           605..647
FT                   /evidence="ECO:0007829|PDB:4IM0"
FT   TURN            648..651
FT                   /evidence="ECO:0007829|PDB:4IM0"
FT   HELIX           680..714
FT                   /evidence="ECO:0007829|PDB:5EP6"
FT   STRAND          715..717
FT                   /evidence="ECO:0007829|PDB:5EP6"
SQ   SEQUENCE   729 AA;  83642 MW;  B58E4FE1B502276D CRC64;
     MQSTSNHLWL LSDILGQGAT ANVFRGRHKK TGDLFAIKVF NNISFLRPVD VQMREFEVLK
     KLNHKNIVKL FAIEEETTTR HKVLIMEFCP CGSLYTVLEE PSNAYGLPES EFLIVLRDVV
     GGMNHLRENG IVHRDIKPGN IMRVIGEDGQ SVYKLTDFGA ARELEDDEQF VSLYGTEEYL
     HPDMYERAVL RKDHQKKYGA TVDLWSIGVT FYHAATGSLP FRPFEGPRRN KEVMYKIITG
     KPSGAISGVQ KAENGPIDWS GDMPVSCSLS RGLQVLLTPV LANILEADQE KCWGFDQFFA
     ETSDILHRMV IHVFSLQQMT AHKIYIHSYN TATIFHELVY KQTKIISSNQ ELIYEGRRLV
     LEPGRLAQHF PKTTEENPIF VVSREPLNTI GLIYEKISLP KVHPRYDLDG DASMAKAITG
     VVCYACRIAS TLLLYQELMR KGIRWLIELI KDDYNETVHK KTEVVITLDF CIRNIEKTVK
     VYEKLMKINL EAAELGEISD IHTKLLRLSS SQGTIETSLQ DIDSRLSPGG SLADAWAHQE
     GTHPKDRNVE KLQVLLNCMT EIYYQFKKDK AERRLAYNEE QIHKFDKQKL YYHATKAMTH
     FTDECVKKYE AFLNKSEEWI RKMLHLRKQL LSLTNQCFDI EEEVSKYQEY TNELQETLPQ
     KMFTASSGIK HTMTPIYPSS NTLVEMTLGM KKLKEEMEGV VKELAENNHI LERFGSLTMD
     GGLRNVDCL
//
